Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended September 30, 2026.

October 21, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Intimation of Board Meeting under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (“the Company”) is scheduled to be held on Wednesday, October 28, 2026 to consider and approve, inter-alia the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended September 30, 2026. Further, in continuation of our letter dated September 25, 2026, regarding Intimation of closure of Trading Window, we would like to inform that the trading window for trading in Securities of the company shall remain closed till October 30, 2026. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance Office